Kalos Management, Inc. Clovis Oncology, Inc. Transaction History

Kalos Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Jun 21, 2022	SELL	$1.43 - $3.14 $20,835 - $45,749	-14,570 Reduced 58.12%	10,500 $21,000
Q4 2021 Feb 03, 2022	BUY	$2.7 - $4.76 $5,589 - $9,853	2,070 Added 9.0%	25,070 $110,000
Q3 2021 Nov 10, 2021	SELL	$4.06 - $5.8 $3,044 - $4,350	-750 Reduced 3.16%	23,000 $101,000
Q4 2020 Feb 11, 2021	SELL	$4.13 - $6.41 $2,065 - $3,205	-500 Reduced 2.06%	23,750 $114,000
Q3 2020 Nov 12, 2020	BUY	$4.82 - $7.72 $964 - $1,544	200 Added 0.83%	24,250 $141,000
Q2 2020 Aug 13, 2020	BUY	$5.69 - $9.69 $31,295 - $53,295	5,500 Added 29.65%	24,050 $162,000
Q1 2020 May 13, 2020	BUY	$3.77 - $11.0 $28,275 - $82,500	7,500 Added 67.87%	18,550 $119,000
Q4 2019 Feb 13, 2020	BUY	$3.0 - $16.43 $33,150 - $181,551	11,050 New	11,050 $114,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Kalos Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kalos Management, Inc. with notifications on news.